JP2025510725A - メルファランフルフェナミド及びシクロデキストリンを含む製剤 - Google Patents

メルファランフルフェナミド及びシクロデキストリンを含む製剤 Download PDF

Info

Publication number
JP2025510725A
JP2025510725A JP2024556113A JP2024556113A JP2025510725A JP 2025510725 A JP2025510725 A JP 2025510725A JP 2024556113 A JP2024556113 A JP 2024556113A JP 2024556113 A JP2024556113 A JP 2024556113A JP 2025510725 A JP2025510725 A JP 2025510725A
Authority
JP
Japan
Prior art keywords
melphalan flufenamide
cyclodextrin
γcd
pharmaceutical preparation
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510725A5 (cg-RX-API-DMAC7.html
Inventor
レーマン、フレデリック
テオドロビッチ、ペーテル
ハンメル、クリスティン
リンゴム、ルネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides Innovation AB
Original Assignee
Oncopeptides Innovation AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Innovation AB filed Critical Oncopeptides Innovation AB
Publication of JP2025510725A publication Critical patent/JP2025510725A/ja
Publication of JP2025510725A5 publication Critical patent/JP2025510725A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024556113A 2022-03-24 2023-03-24 メルファランフルフェナミド及びシクロデキストリンを含む製剤 Pending JP2025510725A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2204171.9 2022-03-24
GBGB2204171.9A GB202204171D0 (en) 2022-03-24 2022-03-24 Novel formulations
PCT/EP2023/057729 WO2023180565A1 (en) 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin

Publications (2)

Publication Number Publication Date
JP2025510725A true JP2025510725A (ja) 2025-04-15
JP2025510725A5 JP2025510725A5 (cg-RX-API-DMAC7.html) 2026-02-19

Family

ID=81449463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556113A Pending JP2025510725A (ja) 2022-03-24 2023-03-24 メルファランフルフェナミド及びシクロデキストリンを含む製剤

Country Status (11)

Country Link
US (1) US20250205155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499049A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510725A (cg-RX-API-DMAC7.html)
KR (1) KR20240161664A (cg-RX-API-DMAC7.html)
CN (1) CN119053323A (cg-RX-API-DMAC7.html)
AU (1) AU2023241241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245985A1 (cg-RX-API-DMAC7.html)
GB (1) GB202204171D0 (cg-RX-API-DMAC7.html)
IL (1) IL315551A (cg-RX-API-DMAC7.html)
MX (1) MX2024011654A (cg-RX-API-DMAC7.html)
WO (1) WO2023180565A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
SI3228319T1 (sl) * 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
WO2020079165A1 (en) 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
IL315551A (en) 2024-11-01
WO2023180565A1 (en) 2023-09-28
KR20240161664A (ko) 2024-11-12
AU2023241241A1 (en) 2024-10-31
CA3245985A1 (en) 2023-09-28
CN119053323A (zh) 2024-11-29
GB202204171D0 (en) 2022-05-11
EP4499049A1 (en) 2025-02-05
US20250205155A1 (en) 2025-06-26
MX2024011654A (es) 2025-01-09

Similar Documents

Publication Publication Date Title
KR100941210B1 (ko) 백금 유도체를 포함하는 제약 제제
JP6257734B2 (ja) デシタビン誘導体製剤
JP6106228B2 (ja) 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液
TW201039865A (en) Lyophilized preparations of proteasome inhibitors
JP6882538B2 (ja) 注射用組成物
CN111093625A (zh) 达托霉素制剂
JP2016521731A (ja) 抗がん剤を含む安定な水溶性医薬組成物
KR20140037932A (ko) 안정화된 보리코나졸 조성물
WO2017013591A1 (en) Stabilized liquid formulation of levothyroxine
US20250205155A1 (en) Formulations comprising melphalan flufenamide and cyclodextrin
EP4055005A1 (en) Liquid melphalan composition
CA2900508C (en) Cabazitaxel composition
CN111107837A (zh) 包含西普尼莫德的肠胃外制剂
EA052092B1 (ru) Препараты, содержащие мелфалана флуфенамид и циклодекстрин
WO2013032184A2 (ko) 피라지노-트리아진 유도체를 포함하는 조성물
JP2023509518A (ja) 安定なシクロデキストリン非含有カルフィルゾミブ配合物
JP2026016486A (ja) 安定なシクロデキストリン不含カルフィルゾミブ処方物
HK1259054A1 (en) Formulations of vancomycin
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法
EA023081B1 (ru) Инъекционная лекарственная форма флупиртина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260210